产品
编 号：F762339
分子式：C20H19N3O4S
分子量：397.45
分子式：C20H19N3O4S
分子量：397.45
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 858979-50-7
产品详情
生物活性：
Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research.
体内研究：
Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex.Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior.Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters.Animal Model:Medial prefrontal dopaminerjic terminal-lesioned CD(SD) IGS male rat
Dosage:0.3 mg/kg
Administration:Oral administration; 0.3 mg/kg; once
Result:Showed longer exploration time of the novel object (65.03%) than that of the familiar object (34.97%) (p<0.001).
Animal Model:ICR mice with cognitive impairment and/or movement disoder
Dosage:0.1 mg/kg
Administration:Oral administration; 0.1 mg/kg; once
Result:Showed a significantly high alternation behavior (69.5%) as compared to the vehicle administration group (59.6%) (p<0.01).
Animal Model:ICR mice with cognitive impairment and/or movement disoder
Dosage:0.1 mg/kg
Administration:Oral administration; 0.1 mg/kg; once
Result:Showed a significantly large maximum contact area and gait area of the left hindpaw as compared to the vehicle administration group (p<0.05), tendency of the maximum contact area and gait area of the right forepaw being large (p<0.1).
Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research.
体内研究：
Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex.Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior.Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters.Animal Model:Medial prefrontal dopaminerjic terminal-lesioned CD(SD) IGS male rat
Dosage:0.3 mg/kg
Administration:Oral administration; 0.3 mg/kg; once
Result:Showed longer exploration time of the novel object (65.03%) than that of the familiar object (34.97%) (p<0.001).
Animal Model:ICR mice with cognitive impairment and/or movement disoder
Dosage:0.1 mg/kg
Administration:Oral administration; 0.1 mg/kg; once
Result:Showed a significantly high alternation behavior (69.5%) as compared to the vehicle administration group (59.6%) (p<0.01).
Animal Model:ICR mice with cognitive impairment and/or movement disoder
Dosage:0.1 mg/kg
Administration:Oral administration; 0.1 mg/kg; once
Result:Showed a significantly large maximum contact area and gait area of the left hindpaw as compared to the vehicle administration group (p<0.05), tendency of the maximum contact area and gait area of the right forepaw being large (p<0.1).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备